Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Current Opinion in Oncology|January 11, 2022
Recent advances in radiosensitivity determinants in melanomaMohammad Krayem, Ghanem E Ghanem, Dirk Van GestelCurrent Opinion in Oncology|July 26, 2021
New horizons in early drugs development in solid cancersNuria Kotecki, Nadège Kindt, Mohammad Krayem, et al.Immune Network|May 2, 2017
Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical ReviewMehdi Najar, Mohammad Krayem, Nathalie Meuleman, et al.Applied Immunohistochemistry & Molecular Morphology : AIMM|December 23, 2017
Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to ClinicMehdi Najar, Mohammad Krayem, Nathalie Meuleman, et al.International Journal of Oncology|August 31, 2016
GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclaxKateřina Vlčková, Jiri Réda, Lubica Ondrušová, et al.Frontiers in Immunology|April 3, 2023
The current understanding of the immune landscape relative to radiotherapy across tumor typesChrysanthi Iliadi, Laurine Verset, Christelle Bouchart, et al.Cancers|April 30, 2021
RTK Inhibitors in Melanoma: From Bench to BedsideMalak Sabbah, Ahmad Najem, Mohammad Krayem, et al.Cancers|December 21, 2017
PRIMA-1 and PRIMA-1<sup>Met</sup> (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesAnne Perdrix, Ahmad Najem, Sven Saussez, et al.European Journal of Cancer (Oxford, England : 1990)|February 25, 2014
Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenibMohammad Krayem, Fabrice Journe, Murielle Wiedig, et al.Cell Communication and Signaling : CCS|September 22, 2023
Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathwaysKhalid Otmani, Redouane Rouas, Laurence Lagneaux, et al.Pageof 4